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The incidence of chronic pancreatitis (CP) is between 2 and 200 per 100,000 persons and shows an increasing trend
year by year. India has the highest incidence of CP in the world at approximately 114 to 200 per 100,000 persons.
The incidence of CP in China is approximately 13 per 100,000 persons. The aim of this review is to assist surgeons
in managing patients with CP in surgical treatment. We conducted a PubMed search for “chronic pancreatitis” and
“surgical treatment” and reviewed relevant articles. On the basis of our review of the literature, we found that CP
cannot be completely cured. The purpose of surgical therapy for CP is to relieve symptoms, especially pain; to
improve the patient’s quality of life; and to treat complications. Decompression (drainage), resection, neuroablation
and decompression combined with resection are commonly used methods for the surgical treatment of CP. Before
developing a surgical regimen, surgeons should comprehensively evaluate the patient’s clinical manifestations,
auxiliary examination results and medical history to develop an individualized surgical treatment regimen.
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Chronic pancreatitis (CP) refers to limiting, segmental,
diffusing, progressive inflammatory damage, necrosis,
and interstitial fibrous lesions of pancreatic parenchyma
caused by many different factors, usually accompanied
by stenosis and dilation of the pancreatic duct, pancre-
atic calcification, and pancreatic stone formation. The
necrosis of pancreatic acinar cells, the atrophy or loss of
pancreatic islet cells, and extensive interstitial fibrosis
will eventually result in the irreversible destruction of
pancreatic morphology and structure as well as exocrine
and endocrine pancreatic insufficiency.
Globally, the incidence of CP is between 2 and 200 per
100,000 persons and shows an increasing trend year by
year [1,2]. India has the highest incidence of CP in the
world at approximately 114 to 200 per 100,000 persons
[2]. The incidence of CP in China is approximately 13
per 100,000 persons [1,2]. It has been reported that
approximately 90% of patients with CP have symptoms
of abdominal pain [3,4]. Although the mechanism of
abdominal pain is still not clear, pancreatic duct* Correspondence: tougao1971@163.com
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unless otherwise stated.hypertension, pancreatic inflammation, and peripan-
creatic immune cell infiltration usually play important
roles in the mechanism of abdominal pain in CP [4,5].
Historically, excess alcohol consumption plays a leading
role in Western countries, accounting for 60% of CP cases.
In China, excess alcohol consumption accounts for ap-
proximately 35% of the cases of CP [6]. According to a
2007 multicenter survey on CP in China, CP caused by
biliary tract diseases accounted for 33.9% of cases; CP
caused by long-term excess alcohol consumption accounted
for 35.4%; and CP caused by pancreatic trauma accounted
for 10.5% [7]. In China, with the continuous improvement
of quality of life, excess alcohol consumption has gradually
replaced biliary tract diseases to become the leading cause
of CP.
On the basis of the histopathological changes in the
pancreas, CP can be classified into three types: (1) chronic
obstructive pancreatitis; (2) chronic calcifying pancreatitis,
the most common type of CP, which includes alcoholic
CP; and (3) chronic inflammatory pancreatitis, including
CP resulting from chronic inflammation of the biliary
tract and stenosis induced by scar formation [8].
Several studies have shown that for the treatment of
patients with CP, surgical treatment is better than endo-
scopic treatment [9-14]. Surgical intervention is usuallyis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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decades; the treatment effect of internal medicine and
endoscopy is poor; abdominal pain is intractable; pan-
creatic cancer cannot be excluded before surgery; or
there are complications involving adjacent organs, such
as duodenal stenosis, bile duct stricture, portal vein
stenosis combined with portal vein hypertension, pancre-
atic necrosis, pancreatic pseudocyst, or pancreatic fistula
[15,16]. Pancreatic necrosis can be classified as pancreatic
parenchymal necrosis alone, peripancreatic tissue necro-
sis, or both.
CP cannot be completely cured. The purpose of surgi-
cal therapy for CP is to relieve symptoms, especially
pain; to improve the patient’s quality of life; and to treat
complications [17]. Generally speaking, decompression
(drainage), resection, neuroablation, and decompression
combined with resection are commonly used methods
for the surgical treatment of CP [18]. The methods of
decompression and surgical resection are reviewed below.
Review
Decompression
When the main pancreatic duct is dilated more than 7
mm and there is no inflammatory pseudotumor at the
pancreatic head, then pancreatic duct hypertension or
parenchymal hypertension may be the mechanism causing
pain. Performing decompression can achieve satisfactory
pain symptom relief [19,20].
DuVal procedure
In 1954, to resolve the pancreatic hypertension problem
in patients with CP, DuVal [21] and Zollinger et al. [22]
independently conducted main pancreatic duct decom-
pression. They performed pancreatic tail resection and
end-to-end or end-to-side pancreaticojejunostomy of the
residual pancreatic end and jejunum to achieve retro-
grade drainage of the pancreatic duct. However, this
method is applicable only to the obstruction of the pan-
creatic duct at the pancreatic head and dilation of the
whole main pancreatic duct. This method is prone to
cause postoperative pancreatic duct stump stenosis; its
effect on stenosis at other pancreatic duct locations is
not good; and the recurrence of pain symptoms is com-
mon. Therefore, this method is rarely used in clinical
practice.
Puestow-Gillesby procedure
In 1958, to solve the problem of recurrent multiple
strictures of the pancreatic duct in the DuVal proced-
ure, Puestow and Gillesby first proposed the Puestow-
Gillesby procedure [23]. In this procedure, the spleen
and pancreatic tail are resected, and the pancreatic
duct is longitudinally opened. The longitudinally opened
pancreatic duct is then connected with the jejunum viaside-to-side pancreaticojejunostomy to drain the pancre-
atic juice and reduce the incidence of late-stage strictures.
The Puestow-Gillesby procedure is used primarily in cases
of multiple strictures or stones in the pancreatic duct.
However, this complex procedure usually results in severe
trauma to patients with CP; therefore, it is not extensively
applied in clinical practice.
Partington-Rochelle procedure
Two years after Puestow and Gillesby proposed the
Puestow-Gillesby procedure, Partington and Rochelle modi-
fied the Puestow-Gillesby procedure. In the Partington-
Rochelle procedure, the whole pancreatic duct is longitu-
dinally opened, and the whole opened pancreatic duct is
connected with the jejunum via side-to-side pancreaticoje-
junostomy. The pancreatic tail and spleen are preserved
[24]. The Partington-Rochelle procedure maximizes the
preservation of the pancreatic tissues and minimizes
the impact on the endocrine and exocrine functions of
pancreas; thus, it is the most extensively applied CP
decompression procedure in clinical practice. A random-
ized controlled trial showed that compared with endoscopic
drainage, pancreaticojejunostomy (the Partington-Rochelle
procedure) has the advantage of providing improvement of
quality of life and pain relief [9]. It was reported that the
postoperative mortality rate and disease incidence of pa-
tients with CP who underwent the Partington-Rochelle
procedure were lower than among those who had the
Puestow-Gillesby procedure, at approximately 3% and
20%, respectively [25]. Short-term follow-up showed that
the pain relief rate after this decompression procedure
was approximately 75%. However, its long-term pain relief
benefit is still not ideal [25].
Resection
Pancreatoduodenectomy
In 1935, Whipple et al. successfully performed pancrea-
toduodenectomy (PD) in one patient with an ampullary
tumor [26]. In 1946, Whipple described the experience
of applying proximal PD in the treatment of patients
with chronic calcifying pancreatitis [27]. The resection
range in this procedure includes the duodenum and
one-third of the distal end of the stomach. This proced-
ure has gradually become a classical proximal PD and is
called the Whipple procedure. In 1935, this PD proced-
ure was first used in a patient with a malignant tumor of
the pancreatic head. Since the classical Whipple proced-
ure was proposed in 1946 and with the continuous im-
provement in its safety, it has increasingly been applied in
the treatment of patients with CP [28]. After more than a
half century of application, the Whipple procedure has
been confirmed as an effective method for treating pain
and complications in CP. In the late 1970s, owing to the
continuous improvement of perioperative preparations,
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sults of three large-scale clinical trials showed that within
4 to 6 years after patients were surgically treated with the
Whipple procedure, the pain relief rate reached 71% to
89%. Although the postoperative mortality rate was lower
than 5%, the incidence of CP was maintained at approxi-
mately 40% [18,29-31].
Pylorus-preserving pancreatoduodenectomy
In 1978, Traverso and Longmire described their experience
with performing pylorus-preserving pancreatoduodenect-
omy (PPPD) in patients with CP [32]. They considered the
normal physiological function of gastric emptying, avoided
complications caused by subtotal gastrectomy, and avoided
the loss of gastric digestion and absorption function, thus
improving the problem of postoperative malnutrition
[32-34]. The resection range of the PPPD procedure is
essentially the same as that of the classical Whipple pro-
cedure. During surgery, the duodenum is transected at 2
cm from the pylorus. The right gastric artery, main gastro-
duodenal artery and corresponding vagus nerve, and right
gastroepiploic artery are preserved. In addition, the stom-
ach, pylorus, and duodenal bulb 1.5 to 2 cm below the pyl-
orus are also preserved. The long-term pain symptoms of
90% of patients can be improved after the PPPD proced-
ure [35,36]. It was reported that temporary gastric
emptying disorders are among the major postoperative
complications [36]. For experienced surgeons, the Whip-
ple procedure and the PPPD procedure are safe and effect-
ive, and the surgical mortality rate is only 2% to 5%, with a
high long-term pain relief rate [19,37].
Distal pancreatectomy
When patients with CP have left pancreatic duct rupture
or suspected malignant tumor masses and the diameter
of the main pancreatic duct is smaller than 5 mm, distal
pancreatectomy (DP) is usually performed. In 1882,
Trendelenburg performed the first DP in one patient
with a pancreatic tumor [38]. In 1913, the Mayo Clinic
formulated the standard DP procedure [39]. The con-
ventional resection range of the distal pancreas includes
the pancreatic body and pancreatic tail. One of the most
common complications after DP is pancreatic stump fis-
tula. Approximately 0% to 7% of patients have this com-
plication after undergoing DP [40-43]. The incidence of
diabetes mellitus in patients with CP after DP is 17% to
85% [44-47]. This procedure has a large resection range
on the pancreas, and the surgery can affect endocrine
and exocrine functions of the pancreas to different de-
grees; therefore, it should be carefully considered.
Middle segment pancreatectomy
When the lesion is at the pancreatic neck and proximal
pancreas, middle segment pancreatectomy (MSP) is thethird surgical method, in addition to the Whipple pro-
cedure and DP procedure. MSP was first proposed by
Guillemin and Bessot in 1957 in a report on their use of
MSP combined with pancreaticojejunostomy in a patient
with CP [48].
The advantages of MSP are the preservation of most
normal pancreatic tissues, low incidence of postoperative
endocrine and exocrine insufficiency, maintenance of
digestive tract continuity, and preservation of the
spleen [49,50]. Warshaw et al. reported performing
MSP in patients with CP and have not yet observed
diabetes mellitus as a complication, and no reports of
diabetes mellitus complications were found from Warshaw
after 1998 [51]. Roggin et al. analyzed 207 patients and
showed that MSP had a postoperative recurrence rate of
33% and an incidence of pancreatic fistula of 22.2%. The in-
cidence of pancreatic fistula in MSP was higher than in PD
and DP [52]. The indications for MSP application are nar-
row; the manipulation involved in the procedure is com-
plex; and experienced pancreatic surgeons are required.
Therefore, MSP needs to be chosen carefully.
Total pancreatectomy
In 1944, for the first time, Priestley et al. successfully
treated a patient with hyperinsulinemia using total pan-
createctomy (TP) [53]. As TP is associated with high
rates of complications, mortality, and loss of pancreatic
function, surgeons have largely abandoned it. TP is chosen
only when CP involves the whole pancreas; there is
insulin-dependent diabetes mellitus, pancreatic function is
lost; there are pancreatic surgical complications (such as
pancreatic fistula or anastomotic leakage); and there is in-
tractable postoperative pain [54,55]. TP tends to result in
brittle diabetes, for which treatment is difficult; hence, TP
combined with islet autotransplantation (IAT) is often
used to minimize or prevent TP-related diabetes. TP com-
bined with IAT can improve the patient’s quality of life
and reduce hypoglycemic episodes.
Decompression combined with resection
Beger procedure
In the early 1970s, Beger, a German surgeon, observed
that inflammatory masses were usually present at pan-
creatic head locations in many patients with CP. In
1972, Beger performed the first duodenum-preserving
pancreatic head resection (DPPHR), also called the Beger
procedure, in a patient with CP. Surgical experiences
with the DPPHR procedure were summarized and pub-
lished in 1980 after Beger had performed a total of 52 of
them [56]. The key steps of DPPHR include transection
of the pancreatic neck above the portal vein, resection of
pancreatic head masses, preservation of the posterior
branch of the gastroduodenal artery to retain the blood
supply of the duodenum, and preservation of the integrity
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compression effect in the common bile duct and duode-
num. The proximal pancreatic duct is ligated, and the
distal end is used for pancreaticojejunostomy. If there is
lower bile duct obstruction, choledochojejunostomy can
also be performed. The advantage of DPPHR is the preser-
vation of the physiological function of the stomach, duo-
denum, and common bile duct [57]. In some experienced
hospitals, the mortality rate of this surgery is low (0% to
3%), and the recurrence rate is 15% to 32% [57,58]. The
DPPHR procedure can achieve 75% to 95% long-term
pain relief [58-60].
Frey procedure
In 1987, a new, modified type of DPPHR, local resection
of the pancreatic head combined with a longitudinal
pancreaticojejunostomy, was first reported by Frey [61].
Thus, it is also called the Frey procedure. The Frey pro-
cedure is a combination of the Beger procedure and
Partington-Rochelle procedure. Compared with the
Beger procedure, the Frey procedure has a smaller resec-
tion range of the pancreatic head. In addition, combined
with side-to-side pancreaticojejunostomy, pancreatic
juice can be drained along the pancreatic duct in the dir-
ection of the pancreatic tail. When patients with CP
have pancreatic duct obstruction at the pancreatic head
and pancreatic tail as well as small inflammatory masses
at the pancreatic head, the Frey procedure can be con-
sidered. The Frey procedure is not applicable when there
are large inflammatory masses at the pancreatic head
and no stenosis of the left pancreatic duct [62]. A retro-
spective randomized controlled trial study showed that
the recurrence rate after the Frey procedure (19%) was
lower than that after PPPD (53%). Another study showed
that the recurrence rate after the Frey procedure (22%)
was lower than that after the Beger procedure (32%).
The 7-year endocrine insufficiency rate after the Frey
procedure (86%) was lower than that after PPPD (96%).
The 8-year endocrine insufficiency rate after the Frey
procedure (78%) was lower than that after the Beger
procedure (88%) [57,58,63,64].
Berne modification
In 2001, to target the condition of portal hypertension in
certain patients with CP, Gloor et al. modified the Beger
procedure and the Frey procedure to develop the Berne
procedure [65]. Resection of pancreatic tissues at the
portal vein level is usually difficult because of inflamma-
tion or portal hypertension. In the Berne procedure, this
resection is not performed. The Berne procedure has a
pancreatic head resection range similar to the Beger pro-
cedure. The pancreatic neck is preserved, and Roux-en-Y
anastomosis is performed between the pancreatic head
and the jejunum. Farkas et al. reported a 10-monthfollow-up study on 30 patients who underwent the
Berne procedure and found no severe complications
[66]. In addition, pancreatic exocrine and endocrine
functions were enhanced after the procedure. A study
on 100 patients with CP who were surgically treated
with the Berne procedure showed a low postoperative
mortality rate (1%) and a low postoperative complication
rate (16%). In the patient sample, 55% had improved post-
operative pain, and 67% had increased body weight. The
treatment effect of the Berne procedure on CP is very ideal
[67]. The operative time and the length of hospitalization in
patients who underwent surgery with the Berne procedure
were both shorter compared with the PPPD and Beger pro-
cedures [68,69]. The Berne procedure is a mature, effective,
and safe surgical procedure with a mortality rate of 0% to
1% and a recurrence rate of 20% to 23% [65].
Imaizumi modification
In 2009, Hatori et al. first proposed a modified Beger pro-
cedure called the Imaizumi procedure [70]. The Imaizumi
procedure is a combination of the Beger procedure and
DPPHR. When treating patients with CP with common
bile duct stenosis, the Imaizumi procedure is particularly
useful. Compared with the conventional Beger procedure,
the Imaizumi procedure has a larger range of resection in
the treatment of common bile duct stenosis in patients
with CP that includes the intrapancreatic bile duct. More
than 90% of patients experience postoperative pain relief.
In addition, compared to the PPPD procedure, the rate of
exocrine and endocrine pancreatic insufficiency associated
with the Imaizumi procedure is lower, but the postopera-
tive complications and mortality rates between these two
exhibited no significant difference. When patients with CP
have pancreatic head masses and bile duct stricture at the
pancreatic head location, the Imaizumi procedure is a use-
ful surgical treatment method.
Hamburg modification
In 1998, Izbicki et al. modified the Frey procedure and
developed the Hamburg procedure [71]. This procedure is
applicable to patients with CP who have thin pancreatic
ducts smaller than 3 mm in diameter. This procedure has
a large range of pancreatic head resection, and the central
part of the uncinate process is also resected. The pancre-
atic tissues are resected in a V shape. This procedure is
safe and effective and can significantly improve the pa-
tient’s postoperative quality of life and establish pain relief
[72,73].
Neuroablative procedure
The pancreatic sympathetic nerve, pancreatic head plexus,
and pancreatic tail plexus jointly innervate the pancreas.
Neuroablation can be considered for patients with CP
without pancreatic duct dilation and pancreatic duct
Ni et al. World Journal of Surgical Oncology  (2015) 13:34 Page 5 of 6stones. When the lesion of a patient with CP is at the
pancreatic head, a pancreatic head plexus resection
can be performed. When the lesion of a patient with
CP is at the pancreatic tail, splanchnicectomy and ce-
liac ganglionectomy can be selectively performed. The
neuroablative procedure has fewer complications, and
the main presentations are gastric emptying disorder,
enteroparalysis, and intestinal motility dysfunction. How-
ever, its effect on long-term pain relief is not ideal; there-
fore, the neuroablative procedure is rarely applied in
clinical practice.
Conclusions
During the surgical treatment of patients with CP, no
matter what type of surgery is performed, the long-term
postoperative pain relief rate, postoperative recurrence
rate and mortality rate, postoperative quality of life, and
postoperative changes in pancreatic endocrine and exo-
crine functions are all issues for clinical surgeons to con-
sider. Therefore, before developing a surgical regimen,
surgeons should comprehensively evaluate the patient’s
clinical manifestations, auxiliary examination results,
and medical history to develop an individualized surgical
treatment regimen.
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